{
    "clinical_study": {
        "@rank": "21555", 
        "arm_group": [
            {
                "arm_group_label": "IW-9179", 
                "arm_group_type": "Experimental", 
                "description": "Oral IW-9179 taken daily for two weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral placebo taken daily for two weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to determine the safety and efficacy of IW-9179\n      administered to patients with functional dyspepsia (FD)."
        }, 
        "brief_title": "Phase 2a Study of IW-9179 to Treat Functional Dyspepsia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Dyspepsia", 
            "Functional Gastrointestinal Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Digestive System Diseases", 
                "Gastrointestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient meets ROME III criteria for functional dyspepsia (FD)\n\n          -  Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening\n             Period or within 2 years of the Screening Visit\n\n          -  Patients who EITHER:\n\n               1. Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening\n                  Visit, OR\n\n               2. Have used a PPI at a stable dose for at least 4 weeks prior to the Screening\n                  Visit;\n\n          -  Patient meets symptom severity criteria in the Pretreatment Period\n\n          -  Patient is fluent and literate in Dutch, French, or English\n\n        Exclusion Criteria:\n\n          -  Patient meets criteria for gastroesophageal reflux disease (GERD, stable regimen of\n             PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis\n\n          -  Patient has a history of inflammatory bowel disease, chronic pancreatitis, small\n             intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic\n             kidney disease, interstitial cystitis, or scleroderma\n\n          -  Any significant neurological disease or a history of cancer (resected basal cell or\n             squamous cell carcinoma of the skin is acceptable; complete remission of other\n             cancers for 5 years or longer is also acceptable)\n\n          -  History of active alcoholism or drug addiction within 12 months prior to the\n             Screening Visit\n\n          -  Hospitalized for a psychiatric condition or has made a suicide attempt during the two\n             years before the Screening Visit\n\n          -  Any organic or structural disease that can cause abdominal pain or discomfort"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712412", 
            "org_study_id": "ICP-112-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "IW-9179", 
                "intervention_name": "IW-9179", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8310"
                    }, 
                    "name": "AZ Sint-Lucas Brugge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }, 
                    "name": "Antwerp University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }, 
                    "name": "Z.O.L. - Campus St. Jan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "UZ Leuven"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mons", 
                        "country": "Belgium", 
                        "zip": "7000"
                    }, 
                    "name": "CHU Ambroise Pare"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roselare", 
                        "country": "Belgium", 
                        "zip": "8800"
                    }, 
                    "name": "H. Hartziekenhuis Roselare-Menen vzw"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almere", 
                        "country": "Netherlands", 
                        "zip": "1311 RL"
                    }, 
                    "name": "FlevoResearch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beek", 
                        "country": "Netherlands", 
                        "zip": "6191 JW"
                    }, 
                    "name": "PreCare Trial and Recruitment"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands", 
                        "zip": "4811 SW"
                    }, 
                    "name": "Andromed Breda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands", 
                        "zip": "5616GB"
                    }, 
                    "name": "Andromed Eindhoven"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9711 SG"
                    }, 
                    "name": "Andromed Noord"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2352 RA"
                    }, 
                    "name": "Andromed Leiden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }, 
                    "name": "Maastricht University Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3021 HC"
                    }, 
                    "name": "Andromed Rotterdam"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Netherlands: Medicines Evaluation Board (MEB)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Rate of treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Reported at any time after the first dose, including the 14 days of treatment and 7 days of follow up"
            }, 
            {
                "measure": "Change from baseline 12-lead electrocardiogram (ECG) at day 14 of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14)"
            }, 
            {
                "measure": "Change from baseline clinical laboratory evaluations at the last day of treatment (day 14)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14)"
            }, 
            {
                "measure": "Change from baseline vital signs at the day 14 visit and at the end of the study (7 days after the last dose)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline values taken prior to first dose (day 1) compared with values taken at the day 14 visit (14 days after first dose) and at the end of the study (21 days after the first dose)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712412"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessments completed at 15 min prior to dose, just prior to dose, and every 15 minutes after the first dose through 240 minutes (4 hours after first dose)", 
                "measure": "Post-meal Symptom Severity (PMSS) Assessment", 
                "safety_issue": "No", 
                "time_frame": "Completed at day 1 and day 14 of the Treatment Period"
            }, 
            {
                "description": "Assessments recorded on a daily basis", 
                "measure": "Daily Patient Symptom Severity (PSS) Assessment", 
                "safety_issue": "No", 
                "time_frame": "Average of daily assessments for the 2 weeks just prior to the first dose compared to: 1) the average of the 2 week treatment period, 2) the average of the first week of treatment and 3) the average of the second week of treatment"
            }, 
            {
                "description": "Assessments recorded on a weekly basis weekly", 
                "measure": "Weekly Symptom Relief (SR) Assessments", 
                "safety_issue": "No", 
                "time_frame": "Average of week 1 and week 2 prior to treatment compared with the week 1 and week 2 during treatment"
            }, 
            {
                "measure": "Nepean Dyspepsia Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline NDI score (collected just prior to first dose) compared with End of Treatment NDI (collected just prior to last dose)"
            }
        ], 
        "source": "Ironwood Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ironwood Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013", 
        "why_stopped": "Slow enrollment"
    }
}